AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06364956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Description: After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Study NCT06323694 — intervention group
Intervention type: BEHAVIORAL
Intervention: quality of life
Description: data collection through questionnaire and interview
Study NCT04711759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
Study NCT04711759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy
Description: Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
Study NCT06281405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w
Study NCT06281405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w
Study NCT06281405 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Short-course radiotherapy: 25Gy/5Fx
Study NCT05649644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trunk Block (SeTB)
Description: Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
Study NCT05649644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block (SC BPB)
Description: Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
Study NCT05010993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nine Hole Peg Test
Description: Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
Study NCT05010993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Purdue Pegboard Test
Description: Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
Study NCT05010993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: Each person will be tested by the Box and Block Test (3 attempts per subtest)
Study NCT05775302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM of Gastrocnemius + Conventional therapy
Description: The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
Study NCT05775302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM of AchillesTendon + Conventional Therapy
Description: Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
Study NCT04604743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention, TBN
Description: The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
Study NCT04997824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-based atrial fibrillation catheter ablation
Description: 1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above.
Study NCT04997824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: 1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure
Study NCT05662735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh repair
Description: Augmentation of hiatal hernia repair with TiMESH® reinforcement
Study NCT05662735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture repair
Description: Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
Study NCT04794556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tight-fitting of KF94 mask with clip
Description: The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
Study NCT05928676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vascanox® HP
Description: Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
Study NCT05652413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted-Engage-PA
Description: Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
Study NCT06248697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1/CTLA4-MSLN-CAR T cells
Description: BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
Study NCT04965506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.
Study NCT04965506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously (SC) once a week.
Study NCT04965506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Dulaglutide administered subcutaneously (SC) once a week.
Study NCT05388019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)
Description: Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
Study NCT05388019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Self-Assessment
Description: Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
Study NCT05737407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LUS-guided choice of Peep
Description: Choice of Peep guided by lung ultrasound to avoid atelectasis
Study NCT05737407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard choice of Peep
Description: Choice of Peep according to standard practice
Study NCT04849819 — intervention group
Intervention type: DRUG
Intervention: Corticosteroids, immunosuppressors, biological agents
Description: We do not prescribe new medications to patients but only observe their adverse effects on the eye.
Study NCT06311110 — intervention group
Intervention type: OTHER
Intervention: Vancouver symptom score for dysfunctional elimination symptoms Questionnaire
Description: Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
Study NCT06311110 — intervention group
Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire
Description: Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.